An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

Stockholm, April 15, 2025 - The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved that promises to slow the speed at which Alzheimer’s erases a person’s ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid plaque that builds up in the brain of Alzheimer's patients and causes ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Within the past few years, the FDA approved two groundbreaking drugs that in trials were shown to reduce brain plaque by 27% ...

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of blockbuster treatments, Mounjaro and Zepbound. Where to invest $1,000 right now?

32,355 people played the daily Crossword recently. Can you solve it faster than others?32,355 people played the daily ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible brain swelling and bleeding. Although the drug is alr ...

Leqembi is an infusion therapy approved by the Food and Drug Administration in 2023. It targets and removes the beta-amyloid ...

Following the launch of the first disease-modifying therapies for Alzheimer’s disease, a key theme at the AD/PD 2025 ...